The Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price target dropped by research analysts at The Goldman Sachs Group from $1.75 to $1.50 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would indicate a […]
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price target dropped by research analysts at The Goldman Sachs Group from $1.75 to $1.50 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would indicate a […]
